Cantor Fitzgerald analyst Elemer Piros raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $24.00 (from $22.00) while maintaining an Overweight rating following the DEXTENZA approval.

Piros commented, "This morning Ocular Therapeutix held a conference call and announced that DEXTENZA 0.4mg has been approved by the FDA for the treatment of ocular pain following ophthalmic surgery. The approval comes approximately four weeks ahead of the 12/28/2018 PDUFA date. With the approval, we believe all manufacturing related issues have been addressed, and now shift the focus to commercialization efforts. Shares are +10% pre-market."